[
  {
    "ts": null,
    "headline": "I-Mab Biopharma Stock: Caution Warranted After Huge Surge",
    "summary": "I-Mab Biopharma surged on promising givastomig results in gastric cancer. Click for my updated look at IMAB stock and why I am remaining neutral.",
    "url": "https://finnhub.io/api/news?id=b80c05aac930259c2b7cffa31faa8a5ffd8940a4dfeb13891be07fce641a90a0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760465752,
      "headline": "I-Mab Biopharma Stock: Caution Warranted After Huge Surge",
      "id": 137089117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "I-Mab Biopharma surged on promising givastomig results in gastric cancer. Click for my updated look at IMAB stock and why I am remaining neutral.",
      "url": "https://finnhub.io/api/news?id=b80c05aac930259c2b7cffa31faa8a5ffd8940a4dfeb13891be07fce641a90a0"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV): Assessing Valuation After Strong 28% Year-to-Date Share Price Jump",
    "summary": "AbbVie (ABBV) shares have delivered solid gains for investors over the past year, rising 22%. The stock has continued its upward trend with a 28% jump year-to-date. The company's recent performance is drawing renewed investor attention. See our latest analysis for AbbVie. With momentum clearly building, AbbVie’s robust 28% share price return year-to-date has added to a steady 22% total return for shareholders over the past year. This reflects growing confidence in the company’s outlook amid...",
    "url": "https://finnhub.io/api/news?id=d019e615118bd1db767ec8cccacc66054d23a3430bdf7a1cc49cc2a96e144223",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760461883,
      "headline": "AbbVie (ABBV): Assessing Valuation After Strong 28% Year-to-Date Share Price Jump",
      "id": 137085595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) shares have delivered solid gains for investors over the past year, rising 22%. The stock has continued its upward trend with a 28% jump year-to-date. The company's recent performance is drawing renewed investor attention. See our latest analysis for AbbVie. With momentum clearly building, AbbVie’s robust 28% share price return year-to-date has added to a steady 22% total return for shareholders over the past year. This reflects growing confidence in the company’s outlook amid...",
      "url": "https://finnhub.io/api/news?id=d019e615118bd1db767ec8cccacc66054d23a3430bdf7a1cc49cc2a96e144223"
    }
  },
  {
    "ts": null,
    "headline": "IGD: Trading Capital Appreciation For Income",
    "summary": "IGD underperforms major equity indices in price appreciation, but its high yield offsets declines when distributions are reinvested. Find out why IGD is a Hold.",
    "url": "https://finnhub.io/api/news?id=c48a0506bfd2802f07af36f5104e50b24e8c5f042ca86e2ea94e13fbc579b925",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760456520,
      "headline": "IGD: Trading Capital Appreciation For Income",
      "id": 137086456,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2213005313/image_2213005313.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "IGD underperforms major equity indices in price appreciation, but its high yield offsets declines when distributions are reinvested. Find out why IGD is a Hold.",
      "url": "https://finnhub.io/api/news?id=c48a0506bfd2802f07af36f5104e50b24e8c5f042ca86e2ea94e13fbc579b925"
    }
  },
  {
    "ts": null,
    "headline": "Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?",
    "summary": "ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.",
    "url": "https://finnhub.io/api/news?id=6a8b7af46b3d6cfb0ab5527d9dc920b0d4a2f26f7e6667e176ab5929df99e608",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760454540,
      "headline": "Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?",
      "id": 137085506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.",
      "url": "https://finnhub.io/api/news?id=6a8b7af46b3d6cfb0ab5527d9dc920b0d4a2f26f7e6667e176ab5929df99e608"
    }
  },
  {
    "ts": null,
    "headline": "Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally?",
    "summary": "Thinking about whether to hold onto AbbVie stock, add more, or take some profits off the table? You're definitely not alone. AbbVie's been turning heads this year, with its share price notching a remarkable 28.3% gain since January and climbing 21.9% over the past 12 months. The momentum has been even more impressive over the long haul, up nearly 230% in five years. Those numbers suggest many investors are feeling more optimistic about AbbVie's growth potential or are reassessing the risks...",
    "url": "https://finnhub.io/api/news?id=e3a3e812d4c2e275882cfbf55ea1e765ff30de7627326cef00f3398d78976deb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760436596,
      "headline": "Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally?",
      "id": 137085597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Thinking about whether to hold onto AbbVie stock, add more, or take some profits off the table? You're definitely not alone. AbbVie's been turning heads this year, with its share price notching a remarkable 28.3% gain since January and climbing 21.9% over the past 12 months. The momentum has been even more impressive over the long haul, up nearly 230% in five years. Those numbers suggest many investors are feeling more optimistic about AbbVie's growth potential or are reassessing the risks...",
      "url": "https://finnhub.io/api/news?id=e3a3e812d4c2e275882cfbf55ea1e765ff30de7627326cef00f3398d78976deb"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again",
    "summary": "Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated look at JNJ stock prospects.",
    "url": "https://finnhub.io/api/news?id=2d338e41d2ed5636b2c4f31ccf41db9670c3f47ddb04a5f8f264d19468c2cead",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760432295,
      "headline": "Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again",
      "id": 137076426,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125573/image_2212125573.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated look at JNJ stock prospects.",
      "url": "https://finnhub.io/api/news?id=2d338e41d2ed5636b2c4f31ccf41db9670c3f47ddb04a5f8f264d19468c2cead"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: The Best Time In Years To Buy This Dividend Powerhouse",
    "summary": "Discover why SCHD's recent underperformance could signal opportunity. Learn why now may be the best time to invest in SCHD.",
    "url": "https://finnhub.io/api/news?id=d87cd0e3b05f44c68962de7185c5a3ebeb759ee76eb9d23f41c8b88286222a71",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760428824,
      "headline": "SCHD: The Best Time In Years To Buy This Dividend Powerhouse",
      "id": 137076239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1480116578/image_1480116578.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why SCHD's recent underperformance could signal opportunity. Learn why now may be the best time to invest in SCHD.",
      "url": "https://finnhub.io/api/news?id=d87cd0e3b05f44c68962de7185c5a3ebeb759ee76eb9d23f41c8b88286222a71"
    }
  },
  {
    "ts": null,
    "headline": "2 Profitable Stocks to Research Further and 1 We Avoid",
    "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
    "url": "https://finnhub.io/api/news?id=efea96c671626badf82b81c8d129997364086af28bda414b37b3fe6061c23c5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760416744,
      "headline": "2 Profitable Stocks to Research Further and 1 We Avoid",
      "id": 137085598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
      "url": "https://finnhub.io/api/news?id=efea96c671626badf82b81c8d129997364086af28bda414b37b3fe6061c23c5a"
    }
  }
]